Početna › Kronična faza mijeloične leukemije › Texas
Kliničke studije za Kronična faza mijeloične leukemije u državi Texas
6 studija za Kronična faza mijeloične leukemije traži sudionike na lokacijama u državi Texas.
Gradovi u državi Texas
Službeni tekst studije (engleski)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06423911Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 2
Od 15 do 80 godina · Oba spola · Ažurirano 30. srp 2026. · NCT02727803A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Baylor Scott and White Research, Temple
U tijeku regrutacijaOpažajna studija
Od 18 do 100 godina · Oba spola · Ažurirano 20. srp 2026. · NCT07091019A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. tra 2026. · NCT05304377A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 12. sij 2026. · NCT06163430Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.